LONDON, UK: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company, Aura Biosciences has announced the pricing of its initial public offering of 5.4 million shares of common stock at a public offering price of $14.00 per share for aggregate gross proceeds of $75.6 million.
In addition, Aura has granted the underwriters an option for a period of 30 days to purchase up to 810,000 additional shares of common stock. All of the shares are being offered by Aura. Aura’s common stock is expected to begin trading on the Nasdaq Global Market on 29 October 2021 under the ticker symbol “AURA”.
The IPO resulted in a £3.7 million (2.8p per share) increase in the value of Arix’s existing holding in Aura, which was valued at £11.7 million at 30 June 2021.